Evaluation of response to different COVID‐19 vaccines in vaccinated healthcare workers in a single center in Iran

Due to the recent coronavirus disease 2019 (COVID‐19) pandemic and emergent administration of various vaccines worldwide, comprehensive studies on the different aspects of vaccines are in demand. This study evaluated antibody response after the second dose of the COVID‐19 vaccine in the Children...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2022-12, Vol.94 (12), p.5669-5677
Main Authors: Pourakbari, Babak, Mirbeyk, Mona, Mahmoudi, Shima, Hosseinpour Sadeghi, Reihaneh H., Rezaei, Nima, Ghasemi, Raheleh, Esfandiari, Fatemeh, Mamishi, Setareh
Format: Article
Language:English
Subjects:
Adult
Antibodies
Antibodies, Neutralizing
Antibodies, Viral
Antibody response
anti‐spike antibody
Child
Coronaviruses
COVAXIN
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
COVID‐19 vaccine
Evaluation
Health care
Health care facilities
Health Personnel
Humans
Infections
Iran - epidemiology
Male
Medical personnel
Middle Aged
Neutralizing
neutralizing antibody
Nucleocapsids
Oxford/AstraZeneca
Pandemics
Personnel
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Severe acute respiratory syndrome-related coronavirus
Sinopharm
Sputnik V
Vaccines
Viral diseases
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Due to the recent coronavirus disease 2019 (COVID‐19) pandemic and emergent administration of various vaccines worldwide, comprehensive studies on the different aspects of vaccines are in demand. This study evaluated antibody response after the second dose of the COVID‐19 vaccine in the Children's Medical Center personnel. The blood samples of 174 healthcare workers were gathered at least 10 days after vaccination. The administered vaccines included Oxford/AstraZeneca, COVAXIN, Sinopharm, and Sputnik V. This study assessed all antibodies employing ELISA methods, including anti‐SARS‐CoV‐2 neutralizing antibody by DiaZist and Pishtazteb kits, anti‐SARS‐CoV‐2‐nucleocapsid by Pishtazteb kit, and anti‐SARS‐CoV‐2‐Spike by Razi kit. The cutoff for the tests' results was calculated according to the instructions of each kit. Totally, 174 individuals with an average age of 40 ± 9 years participated in this study, the proportion of men was 31%, and the frequency of past COVID‐19 infection was 66 (38%). Sixteen (9%) personnel received Oxford/AstraZeneca, 28 (16%) COVAXIN, 29 (17%) Sinopharm, and 101 (58%) Sputnik V. anti‐SARS‐CoV‐2‐nucleocapsid and anti‐SARS‐CoV‐2‐Spike were positive in 37 (21%), and 163 (94%) participants and their mean level were more in adenoviral‐vectored vaccines (p value 
ISSN:0146-6615
1096-9071
1096-9071
DOI:10.1002/jmv.28029